{
    "2020-10-19": [
        [
            {
                "time": "2020-10-19",
                "original_text": "【浙商医药|周报】短期调整下，哪些赛道安全边际高、成长属性强？",
                "features": {
                    "keywords": [
                        "医药",
                        "短期调整",
                        "安全边际",
                        "成长属性"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-10-19",
                "original_text": "重磅|恒瑞医药三季报营收近200亿元，净利润超40亿元！",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "三季报",
                        "营收",
                        "净利润"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-10-19",
                "original_text": "恒瑞医药前三季净利润升14.02%至42.59亿元",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "前三季",
                        "净利润",
                        "增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-10-19",
                "original_text": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
                "features": {
                    "keywords": [
                        "医药生物",
                        "冠脉支架",
                        "国采方案",
                        "头部企业",
                        "受益"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-10-19",
                "original_text": "东吴证券：心脏支架集采即将落地 长期看好国产龙头",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "心脏支架",
                        "集采",
                        "国产龙头"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-10-19",
                "original_text": "医疗行业反腐利剑出鞘！揭开巨额销售费用“画皮”",
                "features": {
                    "keywords": [
                        "医疗行业",
                        "反腐",
                        "销售费用"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-10-19",
                "original_text": "证券时报头版评论：药企须让研发创新站C位",
                "features": {
                    "keywords": [
                        "药企",
                        "研发创新",
                        "C位"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}